London
· Delayed Price · Currency is GBP · Price in GBX Ananda Pharma Company Description
Ananda Pharma Plc, together with its subsidiaries, operates as a biopharmaceutical company that develops cannabidiol-based medicine to treat chronic conditions in the United Kingdom and internationally.
Its lead product, MRX1, is in Phase 2a feasibility trials for endometriosis-related pain and in a Phase 2 efficacy study to investigate chemotherapy-induced peripheral neuropathy.
The company also offers MRX2 and MRX2t, which are cannabinoid-based medicines in Phase 3 clinical trials for refractory epilepsies.
In addition, it engages in crop production; growing of vegetables, melons, and roots and tubers; the wholesale of pharmaceutical goods; the development and distribution of health products; and the manufacture of other organic basic and essential oils.
The company was formerly known as Ananda Developments Plc and changed its name to Ananda Pharma Plc in December 2024.
Ananda Pharma Plc was incorporated in 2018 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2018 |
| Industry | Pharmaceutical Preparations |
| Employees | 12 |
| CEO | Melissa Sturgess |
Contact Details
Address: 60 Gracechurch Street London, EC3V 0HR United Kingdom | |
| Website | anandadevelopments.com |
Stock Details
| Ticker Symbol | ANA |
| Exchange | Aquis Exchange |
| Fiscal Year | February - January |
| Reporting Currency | GBP |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Melissa Sturgess | Chief Executive Officer |
| Jeremy Sturgess-Smith | Chief Financial Officer |